{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T07:51:06Z","timestamp":1794124266601,"version":"4.8.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015068","name":"Universidade de Santiago de Compostela","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015068","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017209","name":"Fundaci\u00f3n Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012513","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.pnpbp.2026.111802","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:01:11Z","timestamp":1782601271000},"page":"111802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["GLP-1 receptor agonists in addiction and affective disorders: Implications for dual disorders"],"prefix":"10.1016","volume":"148","author":[{"given":"Jose","family":"Seijas-Amigo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Salgado-Barreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Eiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Arias-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Rodriguez-Carnero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Ramon","family":"Gonzalez-Juanatey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pnpbp.2026.111802_bb0005","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake","volume":"153","author":"Alhadeff","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.pnpbp.2026.111802_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111802_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13111503","article-title":"GLP-1 receptor agonists and related mental health issues; insights from a range of social media platforms using a mixed-methods approach","volume":"13","author":"Arillotta","year":"2023","journal-title":"Brain Sci."},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111802_bb0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4093\/dmj.2019.0018","article-title":"Glucagon-like Peptide-1 receptor agonist differentially affects brain activation in response to visual food cues in lean and obese individuals with type 2 diabetes mellitus","volume":"44","author":"Bae","year":"2020","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2026.121310","article-title":"The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: a systematic review of systematic reviews and meta-analyses","author":"Ballum","year":"2026","journal-title":"J. Affect. Disord."},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111802_bb0030","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2025.107415","article-title":"The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: a systematic review","volume":"176","author":"Breit","year":"2025","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2026.111802_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review - glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111802_bb0045","article-title":"GLP-1 receptor agonists in mood disorders: a psychiatric perspective","volume":"15","author":"Carmellini","year":"2025","journal-title":"Life (Basel)."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111802_bb0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The antidepressant effects of GLP-1 receptor agonists: a systematic review and Meta-analysis","volume":"32","author":"Chen","year":"2024","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111802_bb0055","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.cmet.2024.09.003","article-title":"GLP-1 programs the neurovascular landscape","volume":"36","author":"Chen","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0060","series-title":"GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration. NCT02302976","author":"ClinicalTrials.gov","year":"2026"},{"key":"10.1016\/j.pnpbp.2026.111802_bb0065","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jpsychires.2023.05.041","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: a systematic review","volume":"164","author":"Cooper","year":"2023","journal-title":"J. Psychiatr. Res."},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111802_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15082081","article-title":"BDNF unveiled: exploring its role in major depression disorder serotonergic imbalance and associated stress conditions","volume":"15","author":"Correia","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111802_bb0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.dsx.2020.03.009","article-title":"Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: a pilot study","volume":"14","author":"Da Porto","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.717824","article-title":"Metabolic syndrome impairs executive function in bipolar disorder","volume":"15","author":"Dalkner","year":"2021","journal-title":"Front. Neurosci."},{"issue":"7","key":"10.1016\/j.pnpbp.2026.111802_bb0085","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.neuropharm.2011.02.028","article-title":"Insulin signalling and addiction","volume":"61","author":"Daws","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2026.111802_bb0090","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s44220-025-00390-x","article-title":"An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders","volume":"3","author":"De Giorgi","year":"2025","journal-title":"Nat. Mental Health"},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111802_bb0095","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.cmet.2011.09.010","article-title":"The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans","volume":"14","author":"De Silva","year":"2011","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111802_bb0100","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s40618-024-02320-7","article-title":"Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial","volume":"47","author":"Dei Cas","year":"2024","journal-title":"J. Endocrinol. Investig."},{"issue":"17","key":"10.1016\/j.pnpbp.2026.111802_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179583","article-title":"Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2025.101203","article-title":"The overlooked mental health burden of polycystic ovary syndrome: neurobiological insights into PCOS-related depression","volume":"78","author":"Dub\u00e9-Zinatelli","year":"2025","journal-title":"Front. Neuroendocrinol."},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111802_bb0120","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111802_bb0125","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/ejn.15992","article-title":"Pro-inflammatory cytokines IL-1\u03b1, IL-6 and TNF-\u03b1 in major depressive disorder: sex-specific associations with psychological symptoms","volume":"57","author":"Elgellaie","year":"2023","journal-title":"Eur. J. Neurosci."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111802_bb0130","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/JCP.0000000000001409","article-title":"Effect of exenatide use on cognitive and affective functioning in obese patients with type 2 diabetes mellitus: exenatide use mediates depressive scores through increased perceived stress levels","volume":"41","author":"Eren-Yazicioglu","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.brainresbull.2022.08.022","article-title":"Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats","volume":"189","author":"Evans","year":"2022","journal-title":"Brain Res. Bull."},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111802_bb0140","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","volume":"59","author":"Farr","year":"2016","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111802_bb0145","doi-asserted-by":"crossref","DOI":"10.1186\/s13722-024-00481-7","article-title":"Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder","volume":"19","author":"Freet","year":"2024","journal-title":"Addict. Sci. Clin. Pract."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111802_bb0150","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-019-2098-3","article-title":"Prediction of psychiatric comorbidity on premature death in a cohort of patients with substance use disorders: a 42-year follow-up","volume":"19","author":"Fridell","year":"2019","journal-title":"BMC Psychiatry."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105179","article-title":"Impact of insulin and insulin resistance on brain dopamine signalling and reward processing - an underexplored mechanism in the pathophysiology of depression?","volume":"149","author":"Gruber","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0160","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.euroneuro.2024.02.003","article-title":"Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: insights from pharmacovigilance measures and unmasking analysis","volume":"82","author":"Guirguis","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0165","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.neuroscience.2025.01.021","article-title":"Disruptions in cellular communication: molecular interplay between glutamate\/NMDA signalling and MAPK pathways in neurological disorders","volume":"569","author":"Gupta","year":"2025","journal-title":"Neuroscience"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111802_bb0170","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/s42255-023-00859-y","article-title":"Liraglutide restores impaired associative learning in individuals with obesity","volume":"5","author":"Hanssen","year":"2023","journal-title":"Nat. Metab."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111802_bb0175","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly Semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111802_bb0180","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70367","article-title":"Target trial emulations of GLP-1 and dual GLP-1\/GIP agonists to reduce major adverse liver outcomes in type 2 diabetes","volume":"45","author":"Henney","year":"2025","journal-title":"Liver Int."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0185","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.physbeh.2019.03.026","article-title":"Central GLP-1 receptors: novel molecular targets for cocaine use disorder","volume":"206","author":"Hernandez","year":"2019","journal-title":"Physiol. Behav."},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111802_bb0190","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111802_bb0195","doi-asserted-by":"crossref","DOI":"10.1080\/23312025.2016.1229086","article-title":"The physiological role of the brain GLP-1 system in stress","volume":"2","author":"Holt","year":"2016","journal-title":"Cogent Biol."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111802_bb0200","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaf028","article-title":"GLP-1 receptor agonists: promising therapeutic targets for alcohol use disorder","volume":"166","author":"Jerlhag","year":"2025","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111802_bb0205","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae167","article-title":"GLP-1 and the neurobiology of eating control: recent advances","volume":"166","author":"Jones","year":"2025","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111802_bb0210","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: from neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"23","key":"10.1016\/j.pnpbp.2026.111802_bb0215","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.pnpbp.2026.111802_bb0220","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111802_bb0225","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111802_bb0230","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/gps.1937","article-title":"Exenatide-induced depression in a geriatric patient","volume":"23","author":"Kohen","year":"2008","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111802_bb0235","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111802_bib413","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/apt.70007","article-title":"Impact of GLP-1 receptor agonists on alcohol-related liver disease development and progression in alcohol use disorder","volume":"61","author":"Kuo","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"3\u20134","key":"10.1016\/j.pnpbp.2026.111802_bb0240","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/00325481.2025.2478812","article-title":"Treating obesity in patients with depression: a narrative review and treatment recommendation","volume":"137","author":"Kushner","year":"2025","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0245","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-Centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.pnpbp.2026.111802_bb0255","article-title":"Case report: semaglutide-associated depression: a report of two cases","volume":"14","author":"Li","year":"2023","journal-title":"Front. Psychol."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0265","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.pnpbp.2026.111802_bb0270","article-title":"Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence","author":"Llach","year":"2025","journal-title":"Mol. Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111802_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115338","article-title":"GLP-1 analogues in the neurobiology of addiction: translational insights and therapeutic perspectives","volume":"26","author":"Marquez-Meneses","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.pnpbp.2026.111802_bb0280","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr5051","article-title":"An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking","volume":"11","author":"Merkel","year":"2025","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111802_bb0285","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.47644","article-title":"Alcohol use and Antiobesity medication treatment","volume":"7","author":"Miller-Matero","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"10.1016\/j.pnpbp.2026.111802_bb0290","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/dom.12963","article-title":"Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials","volume":"19","author":"O\u2019Neil","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111802_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17081036","article-title":"Emerging frontiers in GLP-1 therapeutics: a comprehensive evidence base","volume":"17","author":"Patel","year":"2025","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111802_bb0300","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.neuron.2011.02.009","article-title":"Neuroscience of behavioural and pharmacological treatments for addictions","volume":"69","author":"Potenza","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.pnpbp.2026.111802_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2019.05.044","volume":"257","author":"Pozzi","year":"2019","journal-title":"J. Affect. Disord."},{"issue":"22","key":"10.1016\/j.pnpbp.2026.111802_bb0310","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.pnpbp.2026.111802_bb0315","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2026.111802_bb0320","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-026-01685-5","article-title":"Exploratory associations between co-occurring opioid and alcohol use disorders and GIP\/GLP-1 receptor agonist treatment","author":"Qeadan","year":"2026","journal-title":"Commun. Med."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111802_bb0325","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1360-0443.2012.04010.x","article-title":"Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence","volume":"108","author":"Samet","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2026.111802_bb0330","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s11096-026-02099-y","article-title":"Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA adverse event reporting system","volume":"48","author":"Seijas-Amigo","year":"2026","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0335","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jad.2022.12.089","article-title":"Effects of liraglutide on depressive behaviours in a mouse depression model and cognition in the probe trial of Morris water maze test","volume":"324","author":"Seo","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0340","article-title":"Semaglutide for craving reduction in a cocaine dependent patient: a case report","volume":"1","author":"Sileoni","year":"2025","journal-title":"Clin Neuropsychopharmacol Addict."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0345","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.biopsycho.2017.05.001","article-title":"Role of addiction and stress neurobiology on food intake and obesity","volume":"131","author":"Sinha","year":"2018","journal-title":"Biol. Psychol."},{"key":"10.1016\/j.pnpbp.2026.111802_bb0360","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2022.08.023","article-title":"Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats","volume":"189","author":"Urbanik","year":"2022","journal-title":"Brain Res. Bull."},{"issue":"12","key":"10.1016\/j.pnpbp.2026.111802_bb0365","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2337\/db14-0849","article-title":"GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans","volume":"63","author":"van Bloemendaal","year":"2014","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.pnpbp.2026.111802_bb0370","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can","year":"2014","journal-title":"Int. J. Obes."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111802_bb0375","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1467-789X.2012.01031.x","article-title":"Obesity and addiction: neurobiological overlaps","volume":"14","author":"Volkow","year":"2013","journal-title":"Obes. Rev."},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111802_bb0380","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","article-title":"The neuroscience of drug reward and addiction","volume":"99","author":"Volkow","year":"2019","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111802_bb0385","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/wps.20796","article-title":"Managing dual disorders: a statement by the informal scientific network, UN Commission on narcotic drugs","volume":"19","author":"Volkow","year":"2020","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111802_bb0390","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.pnpbp.2026.111802_bb0395","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study","volume":"29","author":"Wang","year":"2024","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2026.111802_bb0400","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"10","key":"10.1016\/j.pnpbp.2026.111802_bb0405","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob. Res."},{"issue":"3","key":"10.1016\/j.pnpbp.2026.111802_bib412","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.pnpbp.2026.111802_bb0410","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ADM.0000000000001147","article-title":"Feasibility of exenatide, a GLP-1R agonist, for treating cocaine use disorder: a case series study","volume":"17","author":"Yammine","year":"2023","journal-title":"J. Addict. Med."},{"issue":"1","key":"10.1016\/j.pnpbp.2026.111802_bib411","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder","volume":"2","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2026.111802_bib414","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","article-title":"Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study","volume":"207","author":"Mansur","year":"2017","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.pnpbp.2026.111802_bib415","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fpsyt.2018.00784","article-title":"Feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity","volume":"9","author":"Cuomo","year":"2019","journal-title":"Front. Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626002009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584626002009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:25:39Z","timestamp":1785896739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584626002009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":84,"alternative-id":["S0278584626002009"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111802","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists in addiction and affective disorders: Implications for dual disorders","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2026.111802","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111802"}}